[关键词]
[摘要]
Fostamatinib是美国里格尔制药公司开发的一种口服的脾酪氨酸激酶抑制剂,为成年慢性免疫性血小板减少症患者提供了一个全新的治疗方案。其有效性已经被临床试验充分证实,于2018年5月由美国食品药品管理局(FDA)批准上市。概述了fostamatinib的基本性质、合成路线、作用机制、药动学、药物相互作用和临床研究等内容,以期为该类新药研发以及合理用药提供帮助。
[Key word]
[Abstract]
Fostamatinib is an oral spleen tyrosine kinase inhibitor for the treatment of chronic immune thrombocytopenia developed by Rigel pharmaceutical company. Based on positive results in the phase clinical trials, the drug was recently approved by the US FDA in May, 2018 as a treatment for thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment. In this review, the properties, synthetic route, mechanism, pharmacokinetics, drug interactions, and clinical trials of fostamatinib were reviewed to provide reference for new drug discovery and clinical application.
[中图分类号]
[基金项目]